Immix Biopharma (NASDAQ:IMMX) vs. Viking Therapeutics (NASDAQ:VKTX) Head to Head Survey

Viking Therapeutics (NASDAQ:VKTX) and Immix Biopharma (NASDAQ:IMMX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Viking Therapeutics and Immix Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-12.73%	-12.31%
Immix Biopharma	N/A	-102.68%	-80.89%

Institutional and Insider Ownership

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 4.7% of Viking Therapeutics shares are held by company insiders. Comparatively, 48.9% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Viking Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Viking Therapeutics and Immix Biopharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	0	0	11	2	3.15
Immix Biopharma	0	0	1	0	3.00

Viking Therapeutics currently has a consensus price target of $106.75, indicating a potential upside of 162.93%. Immix Biopharma has a consensus price target of $7.00, indicating a potential upside of 211.11%. Given Immix Biopharma’s higher possible upside, analysts plainly believe Immix Biopharma is more favorable than Viking Therapeutics.

Valuation and Earnings

This table compares Viking Therapeutics and Immix Biopharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$85.89 million	($0.93)	-43.66
Immix Biopharma	N/A	N/A	-$15.43 million	($0.85)	-2.65

Viking Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Viking Therapeutics beats Immix Biopharma on 7 of the 12 factors compared between the two stocks.

About Viking Therapeutics

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

About Immix Biopharma

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.